Skip to content
mda-logo_stacked-all white
  • Subscribe
  • Newsletter
  • Advertise
  • MDA.org
  • Donate
Ques_media_logo

Ques_media_logo
Subscribe
Donate

  • Magazine
    • Current Issue
    • Past Issues
  • Featured Content
  • Topics
    • Advocacy
    • Finding a Diagnosis
    • Get Involved
    • Health
    • Inclusion
    • Independence
    • Lifestyle
    • News
    • Personal Stories
    • Science + Research
  • Diseases A-Z
  • Blog
  • Podcast
  • Product Guide
  • Career Quest

Clinical Trials

Blog Post

FDA Approves Sarepta Therapeutics’ Amondys 45 for Treatment of DMD Amenable to Skipping Exon 45

By Sujatha Gurunathan | February 25, 2021
Blog Post

Clinical Trial Alert: Phase 3 Study of Rozanolixizumab in Individuals With Generalized Myasthenia Gravis

By MDA Staff | February 23, 2021
Blog Post

MDA’s 2021 Advocacy Plan

By Mark Fisher | February 2, 2021
Blog Post

Research Study Alert: LGMD2I Natural History Study

By MDA Staff | January 25, 2021
Featured Article

Clinical Trials During COVID 19

By MDA Staff | December 4, 2020
Featured Article

The Search for Inclusion Body Myositis Treatment

By MDA Staff | December 4, 2020
Blog Post

Once a Wild Idea, Successful First-Generation Exon-Skipping Therapies Pave the Way for Personalized Treatments

By Sujatha Gurunathan | November 17, 2020
Blog Post

Scholar Rock Announces Positive Results from Interim Analysis of TOPAZ Phase 2 Study of SRK-015 to Treat SMA

By Sujatha Gurunathan | October 28, 2020
Blog Post

Amylyx Announces More Results from Study of AMX0035 to Treat ALS

By Sujatha Gurunathan | October 19, 2020
Featured Article

Expanding Access to Genetic Testing

By Donna Albrecht | August 14, 2020
  • « Previous
  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • 13
  • …
  • 20
  • Next »
  • Media
  • Careers
  • Donate
  • Contact Quest
muscular-dystrophy-association
Muscular Dystrophy Association, Inc.
1016 W Jackson Blvd #1073
Chicago, IL 60607
800-572-1717 | ResourceCenter@mdausa.org

 

Manage Your Quest Media Subscriptions










The Muscular Dystrophy Association (MDA) is a qualified 501(c)(3) tax-exempt organization. ©2022, Muscular Dystrophy Association Inc. All rights reserved.

Privacy Policy | Terms of Use | State Fundraising Notices

Skip to content
Open toolbar Accessibility Tools

Accessibility Tools

  • Increase TextIncrease Text
  • Decrease TextDecrease Text
  • GrayscaleGrayscale
  • High ContrastHigh Contrast
  • Negative ContrastNegative Contrast
  • Light BackgroundLight Background
  • Links UnderlineLinks Underline
  • Readable FontReadable Font
  • Reset Reset